Securities and Finance

White Collar, Investigations and Enforcement

White Collar, Investigations and Enforcement

NERA economists have extensive experience in applying quantitative economic analysis in white collar criminal investigations and litigation. Our expertise enables us to support firms in all economic aspects of white collar matters, including responding to market abuse investigations, defending enforcement actions, providing expert testimony, and quantifying regulatory impacts and risks.

We have assisted clients with matters involving:

  • Accounting fraud
  • Bid rigging
  • Broker fraud
  • Buyer cartels
  • Commodities trading
  • Criminal option backdating
  • Criminal price fixing
  • Customer and geographic allocation
  • Foreign Corrupt Practices Act (FCPA), UK Bribery Act, and other Anti-Corruption Enforcement
  • Health care/pharmaceutical-related fraud
  • Insider trading
  • Market manipulation
  • Ponzi schemes
  • Stock price manipulation, including "married puts"
  • Tax shelters
  • Trade allocation

We frequently assist clients in responding to formal investigations and requests for data and analyses from regulatory entities, such as the Division of Enforcement at the SEC, the DOJ, offices of State Attorneys General, and self-regulatory organizations such as FINRA. Our capabilities include the construction and analysis of large and complex transaction databases, analysis and implementation of computerized surveillance procedures, and preparation of summary materials in response to regulators' requests. NERA experts' analysis of damages and disgorgement measures aids clients in negotiating settlement agreements.

Our experts have also done extensive research into applying greater precision to calculating the financial benefits of bribery. We can assist clients facing issues arising under the Foreign Corrupt Practices Act (FCPA) and other anti-bribery and anti-corruption laws by offering a more sophisticated economic approach to determining the true "value" of an alleged bribe.

We have supported clients in matters covering a variety of products and services, including agricultural commodities and natural resources, capital equipment, transportation and fuel surcharges, industrial inputs, and consumer goods and services. We also have extensive experience working with mutual fund families in their discussions with regulators; our experts provide economic analysis to aid with the detection of market timing and late trading and the measurement of corresponding losses to mutual fund shareholders. In addition, NERA has worked with specialist firms involved in civil and criminal proceedings. Our experts have extensive experience analyzing data, reports, and algorithms used in automated surveillance of specialists' trading and exchange rules for equities and options.

Name Title Location Phone Email
Dr. Andrew Carron Chairman New York City
London
+1 212 345 5407
+44 20 7659 8500
andrew.carron@nera.com
Lucy P. Allen Managing Director New York City +1 212 345 5913 lucy.allen@nera.com
Dr. Patrick Conroy Managing Director
Chair of NERA's Securities and Finance Practice
New York City +1 212 345 1466 patrick.conroy@nera.com
Dr. Alan Cox Managing Director
Chair of NERA's Intellectual Property Practice
San Francisco
Beijing
Toronto
+1 415 291 1009
+1 415 291 1009
+1 416 868 7314
alan.cox@nera.com
John Garvey Managing Director Chicago +1 312 573 2801 john.garvey@nera.com
Dr. Hiroaki Ishigaki Managing Director Tokyo +81 3 3500 3295 hiroaki.ishigaki@nera.com
Dr. Vinita Juneja Managing Director
Chair of NERA's White Collar, Investigations and Enforcement Practice
New York City
London
Toronto
+1 212 345 3148
+44 20 7659 8618
+1 416 868 7314
vinita.juneja@nera.com
Dr. Denise Neumann Martin Managing Director New York City +1 212 345 5296 denise.martin@nera.com
Dr. Marcia Kramer Mayer Managing Director New York City +1 212 345 2196 marcia.mayer@nera.com
Dr. Chudozie Okongwu Managing Director New York City
London
+1 212 345 5003
+44 20 7659 8568
chudozie.okongwu@nera.com
Dr. Faten Sabry Managing Director
Bankruptcy Practice Chair
New York City
London
+1 212 345 3285
+44 20 7659 8618
faten.sabry@nera.com
Dr. Lauren Stiroh Managing Director
Chair of NERA's Global Antitrust and Competition Practice
White Plains, NY +1 914 448 4143 lauren.stiroh@nera.com
Dr. David Tabak Managing Director New York City +1 212 345 2176 david.tabak@nera.com
Dr. Sharon Brown-Hruska Director Washington, DC +1 202 466 9222 sharon.brown.hruska@nera.com
Richard J. Eichmann Director San Francisco
Los Angeles
+1 415 291 1033
+1 213 346 3009
richard.eichmann@nera.com
Bradley A. Heys Director Toronto
New York City
+1 416 868 7312
+1 212 345 2691
brad.heys@nera.com
Jorge Baez Associate Director New York City +1 305 341 5060 | +1 212 345 5753
+1 305 341 5060
jorge.baez@nera.com
Oksana Kitaychik Associate Director New York City +1 212 345 1094 oksana.kitaychik@nera.com
Timothy McKenna Associate Director New York City +1 212 345 5503 timothy.mckenna@nera.com
Dr. Jordan Milev Associate Director New York City +1 212 345 5516 jordan.milev@nera.com
Robert Patton Associate Director Toronto
London
New York City
+1 416 868 7318
+44 20 7659 8620
+1 212 345 3269
robert.patton@nera.com
Dr. Stephanie Plancich Associate Director New York City +1 212 345 7719 stephanie.plancich@nera.com
Raymund Wong Associate Director New York City +1 212 345 9361 raymund.wong@nera.com
Stefan Boettrich Senior Consultant New York City +1 212 345 1968 stefan.boettrich@nera.com
Dr. Airat Chanyshev Senior Consultant New York City +1 212 345 7336 airat.chanyshev@nera.com
Gary Lambert Senior Consultant London +44 20 7659 8652 gary.lambert@nera.com
Ivelina Velikova Senior Consultant New York City +1 212 345 1160 ivelina.velikova@nera.com
Dr. Jerry Arnold Affiliated Academic Los Angeles +1 310 570 3982 JArnold@marshall.usc.edu
Dr. Paul Wertheim Affiliated Academic Austin
Toronto
Los Angeles
+ 1 512 383 4800
+1 416 868 7314
+1 325 674 2071
paul.wertheim.affiliate@nera.com
Dr. James Overdahl Affiliated Industry Expert Washington, DC +1 202 547 3035 joverdahl@deltastrat.com
Mark L. Berenblut Affiliated Consultant Toronto
New York City
London
+1 416 868 7311
+1 917 475 0020
+44 20 7659 8644
mark.berenblut.affiliate@nera.com
Dr. James Jordan Affiliated Consultant Washington, DC +1 202 466 9263 james.jordan.affiliate@nera.com
Todd Morrison Affiliated Consultant Washington, DC +1 202 466 9213 todd.morrison.affiliate@nera.com
Title Type Author
PDVSA’s Peculiar Oct. ’22 Bond May Carry Elevated Risks Report By Timothy McKenna and Raphael Starr
Securities Class Actions: 2016 Full-Year Review and Mid-2017 Flash Update Published Article By Stefan Boettrich and Svetlana Starykh
BSA/AML Compliance and Enforcement: An Update for the Securities and Derivatives Indu... Published Article By. Sharon Brown-Hruska
Not All MBS Settlements Are Equal White Paper By Faten Sabry, Sungi Lee, and Linh Nguyen
Securities Class Actions Appear to Be Largely ‘Price-Maintenance’ and Omissions Cases White Paper By Dr. David Tabak
Trends in Canadian Securities Class Actions: 2016 Update Report By Bradley A. Heys & Robert Patton
The Use of ABX Derivatives in Credit Crisis Litigation Published Article By Dr. Faten Sabry with Dr. Ethan Cohen-Cole